Bicycle Therapeutics (BCYC)
(Delayed Data from NSDQ)
$22.66 USD
+0.45 (2.03%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $22.60 -0.06 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BCYC 22.66 +0.45(2.03%)
Will BCYC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BCYC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BCYC
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Top 5 Small-Cap Biotechnology Stocks for a Stable Portfolio
BCYC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Bicycle Therapeutics (BCYC) Stock Outpacing Its Medical Peers This Year?
Bicycle Therapeutics (BCYC) Up as PIPE Funding Set to Make $555M
Wall Street Analysts Think Bicycle Therapeutics (BCYC) Could Surge 85.52%: Read This Before Placing a Bet
Other News for BCYC
PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
Remix Therapeutics™ Appoints Maria Koehler, M.D., Ph.D., as an Independent Board Director
Tracking Baker Brothers Portfolio - Q1 2024 Update
Analysts Are Bullish on Top Healthcare Stocks: Bicycle Therapeutics (BCYC), Replimune Group (REPL)